ArticleFrontiers in endocrinology2025
Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The primary objective of this study is to systematically monitor and comprehensively characterize adverse events (AEs) associated with methimazole, which is utilized in the treatment of hyperthyroidism. Method: A comprehensive analysis of the US FDA Adverse Event Reporting System (FAERS) database was conducted, covering data from the first quarter of 2004 to the first quarter of 2025. Multiple signal detection algorithms, including the ROR, PRR, BCPNN, and EBGM, were employed for conduct disproportionality analysis to efficiently mine the data and accurately identify signals associated with AEs related to methimazole. Result: After analyzing 1,908 patient cases with 6,449 reported AEs linked to methimazole, the study confirmed AEs like agranulocytosis, pyrexia, hypothyroidism, and drug-induced liver injury aligning with the drug's package insert. Interestingly, several previously unreported AEs, such as premature baby, polyarthritis, pleural effusion, septic shock, cholestasis and jaundice cholestatic were identified. The findings indicate potential unrecognized AEs and highlight the importance of continued pharmacovigilance and rigorous drug safety surveillance. The median onset time of methimazole related AEs was 27 days (interquartile range [IQR]: 5-58 days), indicating that the majority of cases occurred early after initiating use methimazole. Conclusion: This study confirms that agranulocytosis, pyrexia, exposure during pregnancy, and hyperthyroidism are AEs associated with methimazole use. It also identifies new safety signals, including premature infants, polyarthritis, pleural effusion, septic shock, cholestasis, and cholestatic jaundice, that warrant further investigation. These findings support deeper analysis of the relationship between methimazole and adverse events and may help improve patient safety and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.